Routine Lp(a) testing changed management in most UK lipid clinic patients above 50 mg/dL, even without an Lp(a)-specific drug (Curr Med Res Opin 2026)

Original title: Does routine measurement of lipoprotein(a) in a UK lipid clinic alter management in the absence of Lp(a)-specific therapy?

Curr Med Res Opin · 1 January 2026 · 6

Tridimas A, Ahmed S

This retrospective observational study examined 337 patients at a UK specialist lipid clinic to assess whether routine lipoprotein(a) measurement changes real-world management despite the absence of an approved Lp(a)-lowering therapy. Management changes, medication up-titration, reinforced lifestyle advice, or strengthened emphasis on lifelong lipid-lowering therapy, occurred in 3.5% of patients with Lp(a) below 50 mg/dL, but in 56% of those at 50-89 mg/dL and 79% and 83% of those at 90-179 and 180 mg/dL or above, respectively. Family cascade screening was initiated exclusively in patients with Lp(a) of 90 mg/dL or above, in around a third of that subgroup. Mean final non-HDL-cholesterol rose and target attainment fell with increasing Lp(a) category, likely reflecting Lp(a)-cholesterol's contribution to non-HDL-C rather than under-treatment. The authors argue this real-world management shift, together with cost-effectiveness modelling favouring one-time testing, supports universal Lp(a) measurement.

Original abstract

Background: Elevated lipoprotein(a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite guideline endorsement, its measurement is inconsistently adopted within the UK healthcare setting. Understanding whether identifying raised Lp(a) alters real-world management and lipid outcomes is key to guiding policy.

Objective: To evaluate the distribution of Lp(a) levels in a UK lipid clinic, quantify management changes across clinically relevant thresholds and explore the relationship between Lp(a) and final non-HDL-cholesterol (non-HDL-C) attainment.

Methods: This retrospective observational study included 337 patients attending a specialist lipid clinic. Demographics, atherosclerotic cardiovascular (ASCVD) disease status, HEART UK Lp(a) testing criteria, management actions, and final non-HDL-C values were analyzed. Lp(a) concentrations were initially grouped into five descriptive categories (<30, 30-49, 50-89, 90-179, and ≥180 mg/dL) for baseline characterization. For management-change analyses, categories <50 mg/dL were combined to reflect the ESC/EAS-defined threshold for elevated Lp(a), which served as the clinical reference point for assessing management impact.

Results: Management changes were observed in 3.5% of patients with Lp(a) < 50 mg/dL, 56% with 50-89 mg/dL, and 79% and 83% of those with 90-179 mg/dL and ≥180 mg/dL, respectively. Interventions involved medication up-titration, reinforcement of lifestyle measures, or strengthened clinical emphasis on the importance of lifelong lipid-lowering therapy. Family cascade screening was initiated exclusively among patients with Lp(a) ≥ 90 mg/dL, representing around one-third of this subgroup. Mean final non-HDL-C increased with Lp(a) category, while target attainment (<2.5 mmol/L) declined, likely reflecting the biochemical contribution of Lp(a)-cholesterol to the non-HDL-C fraction rather than suboptimal management.

Conclusions: Routine Lp(a) testing meaningfully alters management and reveals a form of residual dyslipidaemia resistant to standard therapy. These findings, combined with recent cost-effectiveness modelling showing NHS and societal savings from one-time testing, support incorporation of Lp(a) measurement into universal cardiovascular risk assessment.

Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.